Meta-analysis on the possible association between in vitro fertilization and cancer risk
- PMID: 23211423
- DOI: 10.1097/IGC.0b013e318277608b
Meta-analysis on the possible association between in vitro fertilization and cancer risk
Abstract
Objective: We aimed to examine the association between in vitro fertilization (IVF) and risk of cancers through conducting a meta-analysis of cohort studies.
Methods: Relevant studies were identified by using PubMed, ISI Web of knowledge, and Scopus through March 2012. Reference lists from retrieved articles were also reviewed. We included historical cohort studies that reported relative risks (RRs) with 95% confidence intervals (CIs) for the association between IVF and cancer risk. Both fixed- and random-effects models were used to calculate the summary risk estimates.
Results: Eight cohort studies involving 746,455 participants were included in this meta-analysis. The overall combined RRs for women with IVF treatment were 0.99 (95% CI, 0.74-1.32) for all-site cancer, 1.59 (95% CI, 1.24-2.03) for ovarian cancer, 0.89 (95% CI, 0.79-1.01) for breast cancer, and 1.07 (95% CI, 0.45-2.55) for cervical cancer. A beneficial effect was shown in the subgroup of breast cancer meta-analysis compared with women who gave birth (RR, 0.79; 95% CI, 0.65-0.95). Excess risk of ovarian cancer was still observed when analyses were restricted to studies with less than 8 years of follow-up (RR, 2.35; 95% CI, 1.03-5.37) and studies including cancer cases diagnosed within 1 year of the IVF treatment (RR, 1.71; 95% CI, 1.22-2.40). No evidence of substantial publication bias was observed.
Conclusions: This meta-analysis suggests that there is no significant association between IVF and cancer risk. A possible beneficial effect was shown in the subgroup of breast cancer meta-analysis. Excess risk of ovarian cancer was observed in the analysis of all the studies and subgroups. Special attention should be made to women who may be diagnosed with cancer during or shortly after IVF treatment. Studies of high methodological quality with larger population and longer follow-up are required to provide more evidences for a better understanding of the association.
Comment in
-
Methodological remarks on the recent meta-analysis examining the possible association between in vitro fertilization and cancer risk.Int J Gynecol Cancer. 2013 Oct;23(8):1348. doi: 10.1097/01.IGC.0000434237.20482.40. Int J Gynecol Cancer. 2013. PMID: 24257548 No abstract available.
Similar articles
-
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.Cochrane Database Syst Rev. 2020 Dec 21;12(12):CD006105. doi: 10.1002/14651858.CD006105.pub4. Cochrane Database Syst Rev. 2020. PMID: 33347618 Free PMC article.
-
Clinical implications of sperm DNA damage in IVF and ICSI: updated systematic review and meta-analysis.Biol Rev Camb Philos Soc. 2021 Aug;96(4):1284-1300. doi: 10.1111/brv.12700. Epub 2021 Mar 1. Biol Rev Camb Philos Soc. 2021. PMID: 33644978
-
Preterm birth in singleton pregnancies conceived by in vitro fertilization or intracytoplasmic sperm injection: an overview of systematic reviews.Am J Obstet Gynecol. 2024 Nov;231(5):501-515.e9. doi: 10.1016/j.ajog.2024.05.037. Epub 2024 May 23. Am J Obstet Gynecol. 2024. PMID: 38796038 Review.
-
The possible association between in vitro fertilization treatments and cancer development.Int J Gynecol Cancer. 2003 Jan-Feb;13(1):23-7. doi: 10.1136/ijgc-00009577-200301000-00004. Int J Gynecol Cancer. 2003. PMID: 12631215
-
Melanoma risk after ovarian stimulation for in vitro fertilization.Hum Reprod. 2015 May;30(5):1216-28. doi: 10.1093/humrep/dev023. Epub 2015 Mar 4. Hum Reprod. 2015. PMID: 25743782
Cited by
-
Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2022 Sep 13;13:986477. doi: 10.3389/fendo.2022.986477. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176466 Free PMC article.
-
Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.Cochrane Database Syst Rev. 2013 Aug 13;2013(8):CD008215. doi: 10.1002/14651858.CD008215.pub2. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2019 Jun 18;6:CD008215. doi: 10.1002/14651858.CD008215.pub3. PMID: 23943232 Free PMC article. Updated.
-
Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.J Natl Cancer Inst. 2021 Jun 1;113(6):699-709. doi: 10.1093/jnci/djaa163. J Natl Cancer Inst. 2021. PMID: 33769500 Free PMC article.
-
Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.Cochrane Database Syst Rev. 2019 Jun 18;6(6):CD008215. doi: 10.1002/14651858.CD008215.pub3. Cochrane Database Syst Rev. 2019. PMID: 31207666 Free PMC article.
-
Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development.Drug Saf. 2019 Mar;42(3):453-461. doi: 10.1007/s40264-018-0742-3. Drug Saf. 2019. PMID: 30341677 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources